Patients Requiring Abdominopelvic CT With Oral Administration of Contrast
Conditions
Keywords
Oral Isovue
Brief summary
This is a retrospective clinical study with prospectively designed blinded evaluation of CT images in adult and pediatric patients who underwent CT examinations of the abdomen and pelvis and were orally administered a solution of Isovue-300 to opacify the GI tract to distinguish it from adjacent abdominal and pelvic structures. The study will collect already existing data, such as demographic data, adverse events and CT images, for all chronologically enrolled patients who meet the inclusion/exclusion criteria prospectively defined in this protocol
Interventions
DRUGIopamidol
Previously administered Isovue-300 (300 mgI/mL) PO at a dilution of 2-3% (6-9 mgI/mL)
Sponsors
Bracco Diagnostics, Inc
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Inclusion criteria
Patients will be included in the study if: * Demographic and safety data are available for analysis * Complete set of CT images performed after oral administration of Isovue-300 are available for assessment * Isovue-300 was orally administered during an interval time of 60-20 minutes before the CT scanning. Patients will be excluded from the study if: * Oral contrast agent received within 1 week prior to the CT scan * Undergone any abdominopelvic surgery procedure that resulted in alteration of the bowel transit time prior to the CT exam * CT exam with oral administration of Isovue was performed because of a known or suspected condition of bowel obstruction * Patient did not actively drink the contrast solution.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with adequate visualization of anatomic delineation of the GI tract | through study completion, an average of 1 year |
Countries
United States
Outcome results
None listed